Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2015.04.248 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute liver failure after changing oral anticoagulant from apixaban to rivaroxaban.
BMJ Case Rep
April 2021
Department of Nephrology, Monash Medical Centre, Clayton, Melbourne, Victoria, Australia.
Rivaroxaban is a commonly used anticoagulant agent for treatment and prevention of thromboembolism. There are case reports demonstrating an association between its use and drug-induced liver injury. However, this has not been reported in a patient who previously tolerated apixaban.
View Article and Find Full Text PDFSingle-Dose Rivaroxaban-Induced Acute Liver Injury.
Am J Ther
December 2019
Department of Medicine, Mount Sinai West Hospital, Icahn School of Medicine, New York, NY.
Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases.
Eur J Gastroenterol Hepatol
February 2018
Internal Medicine and Hepatology Unit, DIBIMIS.
Aim/objective/background: Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used. Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported.
View Article and Find Full Text PDFRivaroxaban induced liver injury: A cholestatic pattern.
Int J Cardiol
August 2016
Department of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, France; Regional Pharmacovigilance Centre, Strasbourg Regional University Hospital, France. Electronic address:
Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report.
Blood Coagul Fibrinolysis
September 2015
aVeterans Affairs Medical Center, West Palm Beach bVeterans Integrated Service Network 8, Pharmacy Benefits Management, Bay Pines, Florida cUniversity of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.
Postmarketing reports have emerged associating rivaroxaban with drug-induced liver injury (DILI); however, management strategies of patients with suspected rivaroxaban-induced liver injury requiring continued anticoagulation have not been published. The present report describes a 67-year-old male with atrial fibrillation receiving rivaroxaban who developed a 16-fold elevation in alanine transaminase, a nearly two-fold elevation in total bilirubin, and ultrasound confirmed hepatic steatosis. The patient was switched from rivaroxaban to apixaban with subsequent rapid resolution of laboratory abnormalities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!